Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

References

• Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol. 1981;47:553–561.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. Hematol J. 1997;1:53–66.
   Google Scholar
• Slovak M, Kopecky K, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998;92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood. 2011;118:1754–62.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113:4505–4511.
   PubMed Web of Science ®Google Scholar
• Renneville A, Boissel N, Zurawski V et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;115:3719–3727.
   PubMed Web of Science ®Google Scholar
• Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood. 2003;102:1613–1618.
   PubMed Web of Science ®Google Scholar
• Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111:4329–4337.
   PubMed Web of Science ®Google Scholar
• Gari M, Goodeve A, Wilson G, et al. C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105:894–900.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:9234–9242.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431–448.
   PubMed Web of Science ®Google Scholar
• Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740–3746.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733–3739.
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717–2723.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624–633.
   PubMed Web of Science ®Google Scholar
• Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469–2475.
   PubMed Web of Science ®Google Scholar
• Boissel N, Leroy H, Berthon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20:965–970.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106–130.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783–1786.
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009;46:100–106.
   PubMed Web of Science ®Google Scholar
• Schnapp LM. Another notch on the belt. Blood. 2009;113:1615–1616.
   Web of Science ®Google Scholar
• Issa JP DNA methylation as a therapeutic targetin cancer. Clin Cancer Res. 2007;13:1634–1637.
   PubMed Web of Science ®Google Scholar
• Rai KR, Holland JF, Glidewell OG, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood. 1981;58:1203–1212.
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell OJ, Wiernik P, et al. Cytosine arabinoside with daunorubicin and adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60:454–462.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520–2526.
   PubMed Web of Science ®Google Scholar
• Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood. 1987;69:1441–1449.
   PubMed Web of Science ®Google Scholar
• Bishop JF, Lowenthal PM, Joshua D, et al. Etoposide in acute non- lymphoblastic leukemia. Blood. 1990;75:27–32.
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol. 1992;10:1103–1111.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;15:313–319.
   Google Scholar
• Hansen OP, Pedersen-Bjergaard J, Ellegaard G, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients of acute myeloid leukemia: A Danish National phase III trial. Leukemia. 1991;5:510–516.
   PubMed Web of Science ®Google Scholar
• Berman E, Arlin ZA, Gaynor J, et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute non-lymphocytic leukemia: Results of the L-16M protocol. Leukemia. 1989;3:115–121.
   PubMed Web of Science ®Google Scholar
• Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia. 1990;4:177–183.
   PubMed Web of Science ®Google Scholar
• Rees JKH, Gray RG, Wheatley K. Dose intensification in acute myeloid leukemia: greater effectiveness at lower cost. Principle report of the Medical Research Council’s AML9 study. Br J Haematol. 1996;94:89–98.
   PubMed Web of Science ®Google Scholar
• Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with dauno- rubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841–2851.
   PubMed Web of Science ®Google Scholar
• Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710–1717.
   PubMed Web of Science ®Google Scholar
• Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. Br J Haematol. 1992;81:170–177.
   PubMed Web of Science ®Google Scholar
• Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. Blood. 1996;87:4979–4989.
   PubMed Web of Science ®Google Scholar
• Loeb DM, Bowers DC, Civin CI, et al. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia. Med Pediatr Oncol. 2001;37:365–371.
   PubMedGoogle Scholar
• Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116–4124.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Büchner T. Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol. 2001;38(Suppl 6):3–9.
   Google Scholar
• Kern W, Estey EH. High-dose cytarabine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer. 2006;107:116–124.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.
   PubMed Web of Science ®Google Scholar
• Cassileth P, Lynch E, Hines JD, et al. Varying intensity of post-remission therapy in acute myeloid leukemia. Blood. 1992;79:1924–1930.
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22,q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–3775.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone AH, Stevens R, et al. Randomised comparison of addition of autologous bone-marrow transplantation in intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700–708.
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Harrington DP, Appelbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1656.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Cahn JY, Pignon P, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978–2986.
   PubMed Web of Science ®Google Scholar
• Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995;332:217–223.
   PubMed Web of Science ®Google Scholar
• Roboz GJ. N ovel approache s to the treatment of acute myeloid leukemia. Hematology. 2011:43–50.
   Google Scholar
• Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the Cooperative German Transplant Study Group. J Clin Oncol. 2008;26:5183–91.
   PubMed Web of Science ®Google Scholar
• Büchner T, Berdel WE, Schoch C, et al. Late events in AML. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24:2480–2489.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Le Delay MC, Castaigne S, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood. 1993;82:3241–3249.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021–1028.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martin G, Gonzales M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood. 2004;103:1237–1243.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Tallman MS, Lo Cocco F Tricks of the trade for the appropriate management of acute promyelocytic leukemia. Blood. 2005 ;105:3019–3025.
   Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group. Blood. 1999;94:1192–1200.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Petti MC, Lo Cocco F, et al. Induction therapy with idarubicin alone significantly influence event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow up. Blood. 2002;100:3141–3146.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves eventfree survival and overall survival for adults with acute promyelocytic leukemia: North America Leukemia Intergroup Study C9710. Blood. 2010;116:3751–3757.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852–3860.
   PubMed Web of Science ®Google Scholar
• Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (AS203) in the treatment of patients with acute promyelocytic leukemia: The MD Anderson experience. Cancer. 2003;97:2218–2224.
   PubMed Web of Science ®Google Scholar
• Douer D, Tallman MS. Arsenic trioxide: New clinical experience with an old medication in hematological malignancies. J Clin Oncol. 2005;23:2396–2410.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Cocco F. Arsenic trioxide: Its use in the treatment of acute promyelocytic leukemia. Am J Cancer. 2006;5:183–191.
   Google Scholar
• Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328–5335.
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all- trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106:3342–3347.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Labopin M, Gorin NC, et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: A survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2007;39:461–469.
   PubMed Web of Science ®Google Scholar
• Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood. 2009;114:Abstr 790.
   Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtu- zumab ozogamicin: Results of the MRC AML 15 trial. J Clin Oncol. 2011;29:369–377.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50–60 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA) [abstract]. 53rd Annual Meeting of the American Society of Hematology. 2011.
   Google Scholar
• Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clo- farabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28:549–555.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clo- farabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759.
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28:1856–1862.
   PubMed Web of Science ®Google Scholar
• Cortes J, Foran J, Ghirdaladze D, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study [abstract]. Blood. 2009;114: Abstr 636.
   Google Scholar
• Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–2308.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28:556–561.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR- 29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107:7473–7478.
   PubMed Web of Science ®Google Scholar
• Thomas XG, Dmoszynska A, Wierzbowska A, et al. Results from a randomized phase III trial of decitabine versus supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed AML [abstract]. J Clin Oncol. 2011;29(Suppl):Abstr 6504.
   Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–569.
   PubMed Web of Science ®Google Scholar
• Giles F, Vey N, DeAngelo D, et al. Phase 3 randomized, placebocontrolled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009;114:4027–4033.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009;114:1166–1173.
   PubMed Web of Science ®Google Scholar
• Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxan- trone, and bevacizumab. Clin Cancer Res. 2004;10:3577–3585.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Morgan G, Ossenkoppele GJ, et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2010;28:4333–4338.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713–1724.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. Firs-in-man study of CPX- 351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukaemia. J Clin Oncol. 2011;29:979–985.
   PubMed Web of Science ®Google Scholar
• Walsby EJ, Coles SJ, Knapper S, Burnett AK. Topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukaemia cells and acts in synergy with cytarabine. Haematologica. 2011;96:393–399.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743–752.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21:453–461.
   PubMed Web of Science ®Google Scholar
• Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969. J Clin Oncol. 1988;6:1014–1030.
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: A Southwest Oncology Group Study. Leukemia. 2001;15:208–216.
   PubMed Web of Science ®Google Scholar
• Bassan R, Pogliani E, Casula P, et al. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: Prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. Hematol J. 2001;2:117–126.
   PubMedGoogle Scholar
• Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia. 2002;16:1259–1266.
   PubMed Web of Science ®Google Scholar
• Hallbook H, Simonsson B, Ahlgren T, et al. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2002;118:748–754.
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863–871.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–2801.
   PubMed Web of Science ®Google Scholar
• Labar B, Suciu S, Zittoun R, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for patients x50 years old in first complete remission: Results of the EORTC ALL-3 trial. Haematologica. 2004;89:809–817.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–4086.
   PubMed Web of Science ®Google Scholar
• Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood. 2004;104:3028–3037.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia: Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90:1346–1356.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Arnold R, Bohme A, et al. Improve outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003 [abstract]. Blood. 2007:Abstr 110.
   Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard risk acute lymphoblastic leukaemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–1833.
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison. Blood. 2009;113:1375–1382.
   PubMed Web of Science ®Google Scholar
• Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomised trial by the Cancer and Leukemia Group B. Blood. 1984;64:267–274.
   PubMed Web of Science ®Google Scholar
• Nagura E, Kimura K, Yamada K, et al. Nation-wide randomized comparative study of doxrubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1994;33:359–365.
   PubMed Web of Science ®Google Scholar
• Ertel I, Nesbit M, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A report from Children’s Cancer Study Group. Cancer Res. 1979;39:3893–3896.
   PubMed Web of Science ®Google Scholar
• Gaynor PS, Steinherz PG, Bleyer WA, et al. Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1991;19:221–227.
   PubMedGoogle Scholar
• Labar B, Suciu S, Willemze R, et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica. 2010;95:1489–1495.
   Web of Science ®Google Scholar
• Teuffel O, Kuster SP Hunger SP et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25:1232–1238.
   PubMed Web of Science ®Google Scholar
• Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19:269–275.
   PubMedGoogle Scholar
• Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children’s Cancer Group. Blood. 2003;101:3809–3817.
   PubMed Web of Science ®Google Scholar
• Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexam- ethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008;26:1932–1939.
   PubMed Web of Science ®Google Scholar
• Willemze R, Zijlmans JM, den Ottolander GJ, et al. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma. Ann Hematol. 1995;70:71–74.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–561.
   PubMed Web of Science ®Google Scholar
• Cuttner J, Mick R, Budman DR, et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia. 1991;5:425–431.
   PubMed Web of Science ®Google Scholar
• Elonen E, Almqvist A, Hânninen A, et al. Intensive treatment of acute lymphocytic leukaemia in adults: ALL86 protocol [abstract]. Haematologica. 1991;76(Suppl 4):133.
   Google Scholar
• Bassan R, Lerede T, Rambaldi A, et al. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica. 1995;80:280–291.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Tecchio C, Meneghini V et al. Estimated 6-year eventfree survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intense phase II protocol on high induction dose of daunorubicin. Leukemia. 1998;12:144–148.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta analysis. Cancer. 2006;106:2657–2663.
   PubMed Web of Science ®Google Scholar
• Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission. Systematic review and meta-analysis. Cancer. 2010;116:3447–3457.
   PubMed Web of Science ®Google Scholar
• Stock W, Sather H, Dodge RK, et al. Outcome of adolescents and young adults with ALL: A comparison of Children’s Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood. 2000;96(Suppl 1):467a.
   Google Scholar
• Boissel N, Auclerc MF, Lhéritier V et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774–780.
   PubMed Web of Science ®Google Scholar
• DeBont JM, van der Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in The Netherlands. Leukemia. 2004;18:2032–2035.
   PubMed Web of Science ®Google Scholar
• Testi AM, Valsecchi MG, Conter V et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AEIOP) and adult (GIMEMA) protocols [abstract]. Blood. 2004;104(Suppl 1):1954a.
   Google Scholar
• Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer. 2006;47:748–756.
   PubMed Web of Science ®Google Scholar
• Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in relation compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–2825.
   PubMed Web of Science ®Google Scholar
• Tomblyn MB, Arora M, Baker KS, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009;27:3634–3641.
   PubMed Web of Science ®Google Scholar
• Marks DL, Forman SJ, Blume KG, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008;112:426–434.
   PubMed Web of Science ®Google Scholar
• Dahlke J, Kroger N, Zabelina T, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37:155–163.
   PubMed Web of Science ®Google Scholar
• Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–2275.
   PubMed Web of Science ®Google Scholar
• Rocha V Labopin M, Sanz G, et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–2285.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113:2902–2905.
   PubMed Web of Science ®Google Scholar
• Hamaki T, Kami M, Kanda Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant. 2005;35:549–556.
   Web of Science ®Google Scholar
• Stein AS, Palmer JM, O’Donnell MR, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009;15:1407–1414.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–4443.
   PubMed Web of Science ®Google Scholar
• Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102:470–476.
   PubMed Web of Science ®Google Scholar
• Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant. 2009;45:1095–1101.
   Web of Science ®Google Scholar
• Bassan R, Lerede T, Di Bona E, et al. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. Br J Haematol. 1999;104:755–762.
   PubMed Web of Science ®Google Scholar
• Houot R, Tavernier E, Le QH, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology. 2004;9:369–376.
   PubMedGoogle Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper- CVAD and imatinib mesylate. Blood. 2004;103:4396–4407.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460–466.
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005;19:1509–1516.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer. 2007;109:2068–2076.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469–1477.
   PubMed Web of Science ®Google Scholar
• Delannoy A, Delabesse E, Lhéritier V et al. Imatinib and methyl- prednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006;20:1526–1532.
   PubMed Web of Science ®Google Scholar
• De Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109:1408–1413.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Lazarus HM, et al. Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study [abstract]. Blood. 2007;110:10a.
   Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727–734.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Sasaki O, Ichikawa S, et al. Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome- positive acute lyphoblastic leukemia. Biol Blood Marrow Transplant. 2011;17:1093–1097.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Bethge W, et al. Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia: interim results of a randomized phase III GMALL study. Bone Marrow Transplant. 2009;43:S48.
   Web of Science ®Google Scholar
• Burke MJ, Trotz B, Luo X, et al. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009;43:107–113.
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R, Sandmaier BM, et al. Nonmyeloablative conditioning with allogeneic hematopoietic stem cell transplantation for the treatment of high risk acute lymphoblastic leukemia. Haematologica. 2011;96:1113–1120.
   PubMed Web of Science ®Google Scholar
• Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9:123–132.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Pees HW, Radtke H, Schwamborn J, et al. The BFM-protocol for HIV-negative Burkitt’s lymphomas and L3 ALL in adult patients: A high chance for cure. Ann Hematol. 1992;65:201–205.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small non-cleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: Results of Cancer and Leukemia Group B study 9251. J Clin Oncol. 2001;19:4014–4022.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1589.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly-diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004;22:3916–3921.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Malerba L, et al. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). LeukLymphoma. 2005;46:233–238.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingo- somal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006;106:120–127.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Kantarjian HM, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome for patients with de novo Philadelphia negative precursor B-cell acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2009;114:344.
   Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Topp MS, Zugmaier G, Goekbuget N, et al. Report of a phase II trial of single-agent BiTE® antibody blinatumomab in patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2009;114:346.
   Web of Science ®Google Scholar
• Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukaemia. Cancer. 2006;106:2645–2651.
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24:1917–1923.
   PubMed Web of Science ®Google Scholar
• Karp JE, Ricklis RM, Balakrishman K, et al. A phase 1 clinical- laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007;110:1762–1769.
   PubMed Web of Science ®Google Scholar
• Hijiya N, Franklin J, Rytting M, et al. A phase I study of clofarabine in combination with cyclophosphamide and etoposide: a new regimen in pediatric patients with refractory or relapsed acute leukaemia [abstract]. ASCO Meeting Abstracts. 2007;25:9529.
   Google Scholar
• Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005;55:361–368.
   PubMed Web of Science ®Google Scholar
• Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: Biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006;107:473–479.
   PubMed Web of Science ®Google Scholar
• Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: Clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial UKALL XII/ ECOG 2993. Blood. 2009;114:5136–5145.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136–5142.
   PubMed Web of Science ®Google Scholar
• Gandhi V Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106:4253–4260.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukaemia. Science. 2004;306:269–271.
   PubMed Web of Science ®Google Scholar
• De KK, Lahortiga I, Mentens N, et al. In vitro validation of gamma- secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica. 2008;93:533–542.
   Web of Science ®Google Scholar
• Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112:2020–2023.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070–2077.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Guarini A, et al. Dasatinib as first line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients: Final results of the GIMEMA LAL1205 Study [abstract]. Blood. 2008;112:119.
   Google Scholar
• Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib [abstract]. Blood. 2007;110:828A.
   Web of Science ®Google Scholar
• Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109:4016–4019.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Cayuela JM, Recher C, et al. Dasatinib (Sprycel®) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: Results of the first 22 patients included in the EWALL-Ph-01 trial (on behalf of the European Working Group on Adult ALL (EWALL)) [abstract]. Blood. 2008;112:1004–1005.
   Web of Science ®Google Scholar
• Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazol[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4- methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010;53:4701–4719.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR- ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, Deininger M, et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations [abstract]. Blood. 2009;114:264.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Cortes JE, Deininger M, et al. Phase 1 trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies [abstract]. J Clin Oncol. 2010;28(Suppl):6511.
   Google Scholar
• Röllig C, Bornhäuser M, Thiede C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758–2765.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cortes J, Estrov Z, et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011;29:2507–2513.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol. 2011;153:421–436.
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597–1603.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML 11 and LRF AML 14 trials. Br J Haematol 2009;145:598–605.
   PubMed Web of Science ®Google Scholar
• Malfuson JV Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806–1813.
   PubMed Web of Science ®Google Scholar
• Plesa C, Le QH, Chelghoum Y, et al. Prognostic index for older adult patients with newly diagnosed acute myeloid leukemia: The Edouard Herriot Hospital experience. Clinical Leukemia. 2008;2:198–204.
   Google Scholar
• Röllig C, Thiede C, Gratmatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116:971–978.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28–36.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia registry. Blood. 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464–468.
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–1123.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612–618.
   PubMed Web of Science ®Google Scholar
• Larson RA. Acute lymphoblastic leukemia: Older patients and newer drugs. American Society of Hematology. Education Program Book. Hematology. 2005:131–136.
   Google Scholar
• Goekbuget N, Leguay T, Hunault M, et al. First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation [abstract]. Blood. 2008;112:118.
   Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 Study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia [abstract]. Blood. 2007;110:587.
   PubMed Web of Science ®Google Scholar
• Haiat S, Vekhoff A, Marzac C, et al. Improved outcome of adult acute lymphoblastic leukemia treated with a pediatric protocol: results of pilot study [abstract]. Blood. 2007;110:2822.
   Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 1997;3:730–737.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648.
   PubMed Web of Science ®Google Scholar
• Juarez J, Bradstock KF, Gottlieb DJ, et al. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia. 2003;17:1294–1300.
   PubMed Web of Science ®Google Scholar
• Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206–6214.
   PubMed Web of Science ®Google Scholar
• Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114:1340–1343.
   PubMed Web of Science ®Google Scholar
• Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Med. 2006;12:1167–1174.
   PubMed Web of Science ®Google Scholar
• Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5:31–42.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–299.
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J Clin Oncol. 2011;29:591–599.
   PubMed Web of Science ®Google Scholar
• Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306–6315.
   PubMed Web of Science ®Google Scholar
• Pui CH, Williams WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178.
   PubMed Web of Science ®Google Scholar